In the latest trading session, 1.18 million INVO Bioscience Inc (NASDAQ:INVO) shares changed hands as the company’s beta touched 1.42. With the company’s most recent per share price at $1.67 changed hands at -$0.05 or -2.87% at last look, the market valuation stands at $4.13M. INVO’s current price is a discount, trading about -1301.2% off its 52-week high of $23.40. The share price had its 52-week low at $0.50, which suggests the last value was 70.06% up since then. When we look at INVO Bioscience Inc’s average trading volume, we note the 10-day average is 12.38 million shares, with the 3-month average coming to 3.71 million.
Analysts gave the INVO Bioscience Inc (INVO) stock a consensus recommendation rating of a Hold, calculated at a mean rating of 3.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended INVO as a Hold, 0 felt it is a Buy and 0 rated the stock as Underweight. INVO Bioscience Inc’s EPS for the current quarter is expected to be $0.
INVO Bioscience Inc (NASDAQ:INVO) trade information
Instantly INVO was in red as seen in intraday trades today. With action -22.66%, the performance over the past five days has been red. The drop to weekly highs of 2.1900 on Monday, 11/20/23 subtracted -2.87% to the stock’s daily price. The company’s shares are showing year-to-date downside of -80.29%, with the 5-day performance at -22.66% in the red. However, in the 30-day time frame, INVO Bioscience Inc (NASDAQ:INVO) is -21.20% down. Looking at the short shares, we see there were 0.29 million shares sold at short interest cover period of 0.06 days.
The consensus price target for the stock as assigned by Wall Street analysts is $2.00, meaning bulls need an upside of 16.5% from its recent market value. According to analyst projections, INVO’s forecast low is $2.00 with $2.00 as the target high. To hit the forecast high, the stock’s price needs a -19.76% plunge from its current level, while the stock would need to soar -19.76% for it to hit the projected low.
INVO Bioscience Inc (INVO) estimates and forecasts
Year-over-year growth is forecast to reach 243.10% up from the last financial year.
The company’s revenue for the corresponding quarters a year ago was $163k and $146k respectively.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -41.39%. The 2023 estimates are for INVO Bioscience Inc earnings to increase by 66.28%.
INVO Bioscience Inc is expected to release its next quarterly earnings report on November 13.
INVO Bioscience Inc (NASDAQ:INVO)’s Major holders
Vanguard Group Inc holds the second largest percentage of outstanding shares, with 0.21% or 5277.0 shares worth $21129.0 as of Jun 29, 2023.
Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Extended Market Index Fund and Perritt Ultra MicroCap Fund. With 5277.0 shares estimated at $21129.0 under it, the former controlled 0.21% of total outstanding shares. On the other hand, Perritt Ultra MicroCap Fund held about 0.15% of the shares, roughly 3651.0 shares worth around $18108.0.